Back Hepatitis C

Hepatitis C

AbbVie Oral Regimen Cures Nearly All GT1 Hepatitis C, Phase 3 Trials Now Done

AbbVie announced this week that it has completed Phase 3 clinical trials of its interferon-free regimen containing 3 direct-acting antivirals, with or without ribavirin, for the treatment of chronic hepatitis C. Across all studies, between 90% and 100% of participants achieved sustained virological response, usually with 12 weeks of therapy, including hard-to-treat patient groups such as people with HCV subtype 1a and liver cirrhosis.

alt

AASLD, IDSA & IAS-USA Announce New Hepatitis C Treatment Guidelines

The American Association for the Study of Liver Diseases (AASLD), the Infectious Diseases Society of America (IDSA), and the International Antiviral Society-USA (IAS-USA) this week announced the first new hepatitis C treatment guidelines that include next-generation direct-acting antiviral agents recently approved by the FDA. The guidance is available on a new website, HCVguidelines.org, that will enable frequent updates to reflect emerging data.

alt

AbbVie All-oral Combination Cures Most Hepatitis C Patients in Phase 2 Study

An all-oral regimen of AbbVie's experimental HCV drugs ABT-450, ABT-333, and ABT-367 plus ribavirin was well-tolerated and cured 88% of genotype 1 hepatitis C patients with only 8 weeks of therapy, rising to 95% with 12 weeks, according to a report in the January 16, 2014, New England Journal of Medicine.

alt

Daclatasvir + Asunaprevir + BMS-791325 Cures Most Genotype 1 Hepatitis C

An interferon-free oral combination of 3 direct-acting antiviral agents developed by Bristol-Myers Squibb led to sustained virological response in more than 90% of treatment-naive chronic hepatitis C patients with HCV genotype 1a or 1b, according to a report in the February 2014 issue of Gastroenterology.

alt

Daclatasvir + Sofosbuvir Shows High Hep C Cure Rate, New Studies Underway

A dual oral regimen of daclatasvir plus sofosbuvir cured more than 90% of chronic hepatitis C patients without interferon or ribavirin, according to a report in the January 16, 2014, New England Journal of Medicine. A series of new studies of this combination in difficult-to-treat groups including HIV/HCV coinfected people and liver transplant recipients are underway.

alt

Boehringer Ingelheim Halts Testing of Deleobuvir Hepatitis C Regimens

Boehringer Ingelheim will cease development of regimens containing its non-nucleoside hepatitis C virus polymerase inhibitor deleobuvir (formerly BI 207127), the company announced this week.

alt

Hepatitis C Prevalence Varies Widely among U.S. Latino Populations

Hepatitis C occurs at different rates in different Latino and Hispanic groups in the U.S., being highest among Puerto Rican men (nearly 12%) and lowest among South American men (0.4%), according to a report in the January 13, 2014, advance edition of the Journal of Infectious Diseases.

alt

Samatasvir + Simeprevir for Hepatitis C Shows High Early Cure Rate

An interferon-free regimen containing Idenix Pharmaceuticals' hepatitis C virus NS5A inhibitor samatasvir (formerly IDX719) plus the recently approved HCV protease inhibitor simeprevir (Olysio) and ribavirin demonstrated an 85% sustained response rate at 4 weeks post-treatment in the Phase 2 HELIX-1 trial, according to a company announcement.

alt

Daclatasvir + VX-135 May Cure 80% of Genotype 1 Hepatitis C Patients

An all-oral regimen of Bristol-Myers Squibb's hepatitis C virus (HCV) NS4A inhibitor daclatasvir plus Vertex's experimental nucleotide polymerase inhibitor VX-135 -- without interferon or ribavirin -- produced early sustained virological response at 4 weeks post-treatment in 83% of previously untreated genotype 1 patients in a small study, Vertex announced this week.

alt